Practical guidance for incorporating FSH assessment into menopause evaluation and long-term health monitoring.

Written by: Dr. Wendy Warner, MD, FMCP-M

Symphony Natural Health Science and Medical Team

Reviewed by Dr. Deanna Minich, PhD, MS, CNS, FMCP, FACN

Follicle-stimulating hormone (FSH) levels may offer insight into endocrine aging and physiological changes associated with perimenopause, with the most robust research pertaining to its associations with changes in bone health. However, FSH fluctuates considerably across the menstrual cycle and even cycle to cycle, making measurement more challenging. Practical testing considerations, including timing with the menstrual cycle, how often to test, and testing methods, as well as interpretive guidelines, can support FSH's use in clinical practice.

"FSH has traditionally been used to confirm where a woman is in the menopausal transition, but emerging research suggests it may also provide insight into how that transition is unfolding physiologically. The value of FSH isn't in a single number. It's in understanding that number across her menopausal trajectory, within the context of a woman's symptoms, menstrual history, and overall health."

FSH Testing Considerations: Timing, Frequency, and Method

When to Test FSH: Regular vs. Irregular Cycles

FSH is normally measured in the early follicular phase (days 2 to 5) when levels are least affected by cyclical feedback [1]. However, in women experiencing irregular cycles in perimenopause, timing can become tricky. A practical approach is testing whenever the patient can identify the start of bleeding, though in cycles that are considerably irregular, random FSH testing becomes the only practical option. Though menstrual cycle timing can considerably affect FSH levels, research shows that single FSH measurements outside of the ideal follicular window can still be adequate for identifying women at risk for changes in bone health [2].

How Often to Test FSH: Trends vs. Single Measurements

FSH levels can fluctuate considerably during perimenopause, and this variability may even offer insight into the dynamic signaling that characterizes the HPO axis. With this in mind, periodic assessment capturing trends (how FSH is changing) and trajectory (the rate at which it's changing) may provide more meaningful insights than a single measurement. Whereas some women experience relatively stable FSH levels over time, others may experience a moderate or initially high increase followed by a decline [3]. In some instances, a second rise may be experienced in postmenopause. Although research is ongoing, the FSH trajectory may reflect clinical differences in metabolic status, bone health, and symptom burden.

Because FSH has been traditionally included in hormone testing, some women may have existing data spanning several years or even decades.

FSH Testing Methods: Serum vs. Urinary

Serum remains the most widely used method for assessing FSH, though reference ranges may vary by laboratory and assay method [4]. At-home urinary assessment is becoming increasingly available, allowing women to repeatedly measure FSH levels over time [5]. This may be particularly useful for those in perimenopause, when FSH may fluctuate significantly. However, there are no established standardized reference ranges for urinary FSH.

"As clinicians, we're treating women, not laboratory values. FSH can be a valuable tool for understanding endocrine change, particularly when followed over time, but it should always be interpreted alongside the patient's clinical picture. When used thoughtfully, it can help guide earlier conversations about bone health, metabolic changes, and individualized care during the menopause transition."

Table: Reference Laboratory Ranges for FSH (IU/L)

Reference ranges vary by laboratory, assay methodology, and population studied. Functional or integrative guidelines for FSH levels should be interpreted alongside conventional laboratory data.

Integrating FSH with Systemic Physiology

FSH is one component of the hypothalamic-pituitary-gonadal (HPG) axis [8,9], which integrates signals from the brain, ovaries, adipose tissue, bone, immune system, and metabolic pathways [10-15]. Research suggests that rising FSH may precede some of the physical changes associated with menopause, making it an early indicator of endocrine aging [16].

Increasing FSH levels may coincide with changes in:

• Bone health [13]
• Body composition [17]
• Vascular health [18]
• Cognitive health [18]
• Mental health [19]
• Metabolism [12,14]

However, FSH is best interpreted with context [20]. The fuller picture incorporates the entire HPG axis and includes menstrual cycle history, estradiol levels, FSH trend and trajectory, symptom burden, bone turnover markers, and known risk factors for bone and cardiometabolic health. A good example of this is that low-weight women (BMI <20 kg/m²) are at an increased risk of skeletal changes in menopause, yet they may present with FSH levels below the diagnostic threshold for menopause [21-23]. Using only FSH can underestimate risk in this population.

Still, research on how FSH affects physical health in menopause is most robust for bone health. In this instance, stage-specific thresholds are suggested as a more clinically useful tool than general ranges. For the full set of stage-specific thresholds and what they mean for skeletal risk, see The Bone-FSH Connection: Why Lumbar Spine Loss May Begin Years Before Menopause. When FSH is modestly elevated, a clinician may recommend proactive care, such as early bone mineral density scans, a review of skeletal risk factors, or dietary and lifestyle changes.

Clinical Applications

These considerations point to a practical approach for using FSH in clinical practice. Rather than using FSH as a single diagnostic tool, clinicians can use it as one input in a more extensive assessment of endocrine aging.

In practice, this may look like:

• Testing in the early follicular phase, when cycles are still somewhat regular, and shifting to random testing when it is the only practical option.
• Establishing an early baseline and tracking trends and trajectories over time, rather than relying on a single point in time. This may be more clinically meaningful than a single measurement and can be especially informative when years of data already exist.
• Using stage-specific thresholds to assess skeletal risk and initiating proactive care when thresholds are exceeded.
• Interpreting FSH within context, using factors such as estradiol, menstrual history, symptom burden, and bone turnover markers, may offer more complete insight into the physical changes occurring during menopause.

Used this way, FSH becomes less of a single number to interpret and more of an integrative signal that provides insight into endocrine adaptations during menopause.

Dr. Wendy Warner

MD, FMCP-M · Symphony Medical Team · Southeastern PA, telemedicine practice · 36 years in practice

Board-certified OB/GYN and functional medicine gynecologist. MD, University of Tennessee Health Science Center; OB/GYN residency, Temple University Hospital. Founded Medicine in Balance after 14 years in conventional practice; moved fully to telemedicine in 2022. Board certified in both gynecology and integrative holistic medicine, past president of the American Board of Integrative Holistic Medicine, authored the menopause chapter in Rakel's Integrative Medicine (5th ed.), co-author of Boosting Your Immunity for Dummies. Trained herbalist; faculty for David Winston's Center for Herbal Studies and educator for the Institute for Functional Medicine’s Hormone Advanced Practice Module. Nationally recognized speaker and educator.

References

1. Infertility Workup for the Women's Health Specialist: ACOG Committee Opinion, Number 781. Obstet Gynecol. 2019;133(6):e377-e384. doi:10.1097/AOG.0000000000003271
2. Shieh A, Greendale GA, Cauley JA, Karvonen-Gutierrez C, Crandall CJ, Karlamangla AS. J Bone Miner Res. 2019;34(12):2246-2253. doi:10.1002/jbmr.3856
3. Lima SM, Yue Y, Bea JW, et al. Menopause. 2026;33(1):3-11. Published 2026 Jan 1. doi:10.1097/GME.0000000000002631
4. Sturgeon CM, Ellis AR. Mol Cell Endocrinol. 2007;260-262:301-309. doi:10.1016/j.mce.2006.09.004
5. Hart RJ, D'Hooghe T, Dancet EAF, et al. Reprod Sci. 2022;29(11):3147-3160. doi:10.1007/s43032-021-00754-5
6. Follicle-stimulating hormone (FSH). Medscape. Accessed July 21, 2026. https://emedicine.medscape.com/article/2089048-overview.
7. Follicle-Stimulating Hormone (FSH), Serum. Mayo Clinic Laboratories. Accessed July 21, 2026. https://www.mayocliniclabs.com/test-catalog/overview/602753#clinical-and-interpretive
8. Buckler H. J Br Menopause Soc. 2005;11(2):61-65. doi:10.1258/136218005775544525
9. Burger HG. Eur J Endocrinol. 1994;130(1):38-42. doi:10.1530/eje.0.1300038
10. Ryu V, Gumerova A, Korkmaz F, et al. Elife. 2022;11:e79612. Published 2022 Sep 2. doi:10.7554/eLife.79612
11. Orlowski M, Sarao MS. Treasure Island (FL): StatPearls Publishing; May 1, 2023.
12. Lee SW, Hwang IS, Jung G, Kang HJ, Chung YH. Medicine (Baltimore). 2022;101(18):e29216. Published 2022 May 6. doi:10.1097/MD.0000000000029216
13. Li L, Pi YZ, Zhang H, et al. J Clin Lab Anal. 2023;37(9-10):e24899. doi:10.1002/jcla.24899
14. Gao L, Wu X, Zhu X, Jin Q, Ma Q, Sun A. Gynecol Endocrinol. 2018;34(12):1035-1038. doi:10.1080/09513590.2018.1482868
15. Kim SM, Sultana F, Sims S, et al. J Endocrinol. 2024;262(1):e230377. Published 2024 May 16. doi:10.1530/JOE-23-0377
16. Harlow SD, Gass M, Hall JE, et al. J Clin Endocrinol Metab. 2012;97(4):1159-1168. doi:10.1210/jc.2011-3362
17. Liu XM, Chan HC, Ding GL, et al. Aging Cell. 2015;14(3):409-420. doi:10.1111/acel.12331
18. Wang Z, Yao H. Int J Womens Health. 2026;18:571490. Published 2026 Mar 13. doi:10.2147/IJWH.S571490
19. Spicer J, Malaspina D, Blank SV, Goosens KA. Psychiatry Res. 2025;345:116239. doi:10.1016/j.psychres.2024.116239
20. Testing and interpreting measures of Ovarian Reserve: A committee opinion. American Society for Reproductive Medicine. Accessed July 20, 2026. https://www.asrm.org/practice-guidance/practice-committee-documents/testing-and-interpreting-measures-of-ovarian-reserve-a-committee-opinion-2020/.
21. Stockman SL, Ayinon CM, Nawash B, et al. Climacteric. Published online March 16, 2026. doi:10.1080/13697137.2026.2631509
22. Asomaning K, Bertone-Johnson ER, Nasca PC, Hooven F, Pekow PS. J Womens Health (Larchmt). 2006;15(9):1028-1034. doi:10.1089/jwh.2006.15.1028
23. Wu SF, Du XJ. Med Sci Monit. 2016;22:145-151. Published 2016 Jan 14. doi:10.12659/msm.895512